Abstract
Objective
The implementation of NTBC into treatment of hypertyrosinemia type I (HT I) greatly improved survival by prevention of acute liver failure and hepatocellular carcinoma. However, there are first reports of cognitive impairment in patients with elevated plasma tyrosine concentrations.
Methods
We here assess the neurocognitive development using standardized psychometric test batteries with respect to cognition, motor abilities and speech in nine early-treated patients with HT I under long-term NTBC treatment.
Results
High plasma tyrosine concentrations were frequently documented resulting in elevated 12-month median plasma tyrosine concentrations in seven out of nine patients. Plasma NTBC concentrations were generally in the lower therapeutic range. Five out of seven patients (71%) above 3 years of age had a total IQ score below the average. In addition, five out of seven patients above 3 years showed an inhomogenous test profile with significant differences between the different testing scales. Motor abilities were subnormal in four out of seven patients(57%). Cerebral MRI revealed no abnormalities. Logopedic evaluation in children at school age documented dysfunction or retardation in language development in all but one of the tested patients (80%), however, all but one patients had a migration background.
Conclusions
A high number of patients performed below normal in the assessment of development, motor function and speech. We propose intellectual impairment as long-term complication in HT type I with elevated plasma tyrosine under NTBC treatment as observed in other hypertyrosinemias. These findings remain to be reproduced in greater patient numbers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Dhalimy M, Overturf K, Finegold M, Grompe M (2002) Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab 75:38–45
Anonymous (2007) Nitisinone: new drug. Type 1 tyrosinemia: an effective drug. Prescrire Int 16:56–58
Bayley N (2006) Bayley scales of infant and toddler development, 3rd edn. Psychological Corporation, San Antonio
Ellaway CJ, Holme E, Standing S et al (2001) Outcome of tyrosinaemia type III. J Inherit Metab Dis 24:824–832
Hall MG, Wilks MF, Provan WM, Eksborg S, Lumholtz B (2001) Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol 52:169–177
Henderson S, Sugden DA (2007) Movement assessment battery for children 2. Psychological Corporation, San Antonio
Herebian D, Spiekerkötter U, Lamshöft M, Thimm E, Laryea M, Mayatepek E (2009) Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients. J Chromatogr B Analyt Technol Biomed Life Sci 877:1453–1459
Holme E, Lindstedt S (1998) Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 21:507–517
Holme E, Lindstedt S (2000) Nontransplant treatment of tyrosinemia. Clin Liver Dis 4:805–814
Hunziker N (1980) Richner-Hanhart syndrome and tyrosinemia type II. Dermatologica 160:180–189
Kaufman AS, Kaufman NL (1983) Kaufman assessment battery for children. Interpretive Manual. Circle Pines, MN: American Guidance Service
Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813–817
Macsai MS, Schwartz TL, Hinkle D, Hummel MB, Mulhern MG, Rootman D (2001) Tyrosinemia type II: nine cases of ocular signs and symptoms. Am J Ophthalmol 132:522–527
Masurel-Paulet A, Poggi-Bach J, Rolland MO et al (2008) NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 31:81–87
Melchers P, Preuss U (1991) Kaufman Assessment Battery for Children: K-ABC: Interpretationshandbuch. Swets and Zeitlinger, Frankfurt
Mitchell GA, Grompe M, Lambert M, Tanguay RM (2001) Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D et al (eds) The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, pp 1777–1805
Petermann F (2008) Movement assessment battery for children-2 (Movement ABC-2). Pearson PLC, Frankfurt
Sener RN (2005a) Tyrosinemia: computed tomography, magnetic resonance imaging, diffusion magnetic resonance imaging, and proton spectroscopy findings in the brain. J Comput Assist Tomogr 29:323–325
Sener RN (2005b) Brain magnetic resonance imaging in tyrosinemia. Acta Radio 46:618–620
Sgaravatti AM, Vargas BA, Zandoná K et al (2008) Tyrosine promotes oxidative stress in cerebral cortex of young rats. Int J Dev Neurosci 26:551–559
Snijders JT, Snijders-Oomen N (1977) Snijders-Oomen nicht-verbale Intelligenztestreihe S.O.N. 2.5-7. Groningen: Wolters-Noordhoff
Tellegen PJ, Laros JA, Petermann F (2007) Snijders-Oomen Non-verbaler Intelligenztest von 2½ bis 7 Jahren (SON-R 2½ - 7). Handanweisung und deutsche Normen, 2nd edn. Hogrefe, Göttingen
Thimm E, Herebian D, Assmann B, Klee D, Mayatepek E, Spiekerkoetter U (2011) Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I. Mol Genet Metab 102:122–125
van Spronsen FJ, Smit GP, Wijburg FA, Thomasse Y, Visser G, Heymans HS (1995) Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation. J Inherit Metab Dis 18:111–114
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by: Bruce A. Barshop
Competing interest: None declared.
Rights and permissions
About this article
Cite this article
Thimm, E., Richter-Werkle, R., Kamp, G. et al. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. J Inherit Metab Dis 35, 263–268 (2012). https://doi.org/10.1007/s10545-011-9394-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-011-9394-5